Bay Area patients racing to lose weight with blockbuster GLP-1 drugs like semaglutide and tirzepatide may be paying an unexpected price at the bathroom drain. A new UCSF-coauthored review says hair shedding is showing up often enough that doctors should start talking about it with patients, especially during periods of rapid weight loss. The good news, dermatologists say, is that for most people it appears to be temporary.
What The Review Found
The paper, published this month in Science Progress, pulled together clinical trials, pharmacovigilance reports and observational studies. It found that non-scarring hair loss, most often telogen effluvium and androgenetic alopecia, has been reported more frequently in people taking semaglutide and tirzepatide than in those who were not. According to Science Progress, the authors saw plenty of variation across studies, yet said the pattern was consistent enough that clinicians should proactively counsel patients about the possibility of shedding.
What Earlier Meta-Analyses Show
An independent 2025 meta-analysis of randomized trials also picked up a signal. That review reported a statistically higher risk of alopecia among people randomized to GLP-1 therapy, estimating about a 3.4-fold increase compared with control groups. The authors stressed that many trials did not prespecify dermatologic outcomes, which makes the size and cause of the effect harder to pin down. Details are available in JAAD Reviews.
Local Dermatologist's Take
Dr. Paradi Mirmirani, a Kaiser Permanente dermatologist and volunteer associate professor at UCSF, told SFGATE that the signal appears “strongest” in patients on higher obesity doses or in those dropping weight very fast.
"Hair shedding can occur with some GLP-1 medications, especially with rapid weight loss, but it is usually temporary, reversible, and manageable," she said. Her advice: aim for steady, sustainable weight loss and pay close attention to nutrition while on these drugs.
How Weight Loss Can Trigger Shedding
Dermatologists point to telogen effluvium as the most likely culprit, rather than a direct toxic effect of the medications themselves. In telogen effluvium, a stressor such as rapid weight loss or nutritional strain pushes more hairs than usual into a resting phase, so they fall out a few months later. The Cleveland Clinic explains that this pattern typically shows up several months after the triggering event and often improves once the body’s nutritional and metabolic stress eases. As part of the workup, clinicians commonly check iron and ferritin levels, vitamin B12 and thyroid function.
What The Drug Labels Say
The WEGOVY prescribing information lists hair loss among adverse reactions observed in clinical trials, at about 3.3% in people taking the 2.4 mg dose compared with 1% on placebo, and notes that these events were associated with weight reduction. The OZEMPIC label lists “alopecia” under postmarketing experience. Those documents are available on the WEGOVY label and the OZEMPIC label.
Practical Steps For Patients
Doctors caution patients not to stop a prescribed GLP-1 drug on their own if they notice extra hair in the shower. Instead, they recommend raising the issue with the prescribing clinician and considering some basic labs, including ferritin or iron, vitamin B12 and TSH, along with a nutrition review to confirm adequate protein and calorie intake.
The Science Progress review, along with input from practicing dermatologists, suggests topical minoxidil as a tool for managing active shedding while weight stabilizes. They also urge patients to avoid prolonged severe caloric restriction, which can worsen telogen effluvium.
For Bay Area patients and prescribers, the message from UCSF-affiliated authors and local dermatologists lands somewhere between caution and reassurance. Be aware of the risk, screen for nutritional contributors and manage shedding early so patients can weigh the benefits of GLP-1 therapy against what is, in most cases, a temporary and treatable hair-loss side effect.
